3.75
price up icon7.45%   0.26
after-market Handel nachbörslich: 3.75
loading
Schlusskurs vom Vortag:
$3.49
Offen:
$3.46
24-Stunden-Volumen:
8.65M
Relative Volume:
1.86
Marktkapitalisierung:
$901.42M
Einnahmen:
$38.03M
Nettoeinkommen (Verlust:
$-146.40M
KGV:
-7.2115
EPS:
-0.52
Netto-Cashflow:
$-121.38M
1W Leistung:
-1.32%
1M Leistung:
+75.23%
6M Leistung:
+23.76%
1J Leistung:
+35.38%
1-Tages-Spanne:
Value
$3.37
$3.77
1-Wochen-Bereich:
Value
$3.28
$3.87
52-Wochen-Spanne:
Value
$1.8906
$4.085

Abcellera Biologics Inc Stock (ABCL) Company Profile

Name
Firmenname
Abcellera Biologics Inc
Name
Telefon
(604) 559-9005
Name
Adresse
150 W 4TH AVENUE, VANCOUVER
Name
Mitarbeiter
596
Name
Twitter
Name
Nächster Verdiensttermin
2024-11-18
Name
Neueste SEC-Einreichungen
Name
ABCL's Discussions on Twitter

Vergleichen Sie ABCL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ABCL
Abcellera Biologics Inc
3.75 901.42M 38.03M -146.40M -121.38M -0.52
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
457.03 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
547.74 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
329.77 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
545.11 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
244.32 28.51B 3.81B -644.79M -669.77M -6.24

Abcellera Biologics Inc Stock (ABCL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-20 Herabstufung The Benchmark Company Buy → Hold
2024-02-22 Hochstufung The Benchmark Company Hold → Buy
2023-12-05 Eingeleitet KeyBanc Capital Markets Overweight
2023-11-06 Herabstufung The Benchmark Company Buy → Hold
2023-10-13 Fortgesetzt Piper Sandler Overweight
2023-02-28 Eingeleitet Cowen Outperform
2022-12-15 Eingeleitet Goldman Buy
2022-11-16 Eingeleitet Truist Buy
2021-12-21 Eingeleitet The Benchmark Company Buy
2021-11-19 Eingeleitet Piper Sandler Overweight
2021-01-05 Eingeleitet BMO Capital Markets Outperform
2021-01-05 Eingeleitet Berenberg Buy
2021-01-05 Eingeleitet Credit Suisse Outperform
2021-01-05 Eingeleitet SVB Leerink Outperform
2021-01-05 Eingeleitet Stifel Buy
Alle ansehen

Abcellera Biologics Inc Aktie (ABCL) Neueste Nachrichten

pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor - Investing.com Australia

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks

Jun 13, 2025
pulisher
Jun 13, 2025

AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha

Jun 13, 2025
pulisher
Jun 12, 2025

ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN

Jun 12, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 09, 2025

AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN

Jun 09, 2025
pulisher
Jun 09, 2025

Squarepoint Ops LLC Acquires 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World

Jun 09, 2025
pulisher
Jun 03, 2025

AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN

Jun 03, 2025
pulisher
Jun 03, 2025

AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance

Jun 03, 2025
pulisher
Jun 02, 2025

Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - AOL.com

Jun 02, 2025
pulisher
Jun 02, 2025

AbCellera (ABCL) Stock Rises on Health Canada Approval - GuruFocus

Jun 02, 2025
pulisher
May 31, 2025

AbCellera gains Health Canada nod for AD antibody trial By Investing.com - Investing.com South Africa

May 31, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace

May 30, 2025
pulisher
May 30, 2025

AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus

May 30, 2025
pulisher
May 30, 2025

AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial - TipRanks

May 30, 2025
pulisher
May 30, 2025

AbCellera gains Health Canada nod for AD antibody trial - Investing.com

May 30, 2025
pulisher
May 30, 2025

Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLC - Defense World

May 30, 2025
pulisher
May 30, 2025

AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN

May 30, 2025
pulisher
May 29, 2025

AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault

May 29, 2025
pulisher
May 20, 2025

13 Best Multibagger Stocks to Invest in Now - Insider Monkey

May 20, 2025
pulisher
May 18, 2025

Truist Financial Has Lowered Expectations for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World

May 18, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia

May 16, 2025
pulisher
May 16, 2025

Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 16, 2025

Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus

May 16, 2025
pulisher
May 15, 2025

Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech

May 15, 2025
pulisher
May 15, 2025

Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st

May 15, 2025
pulisher
May 15, 2025

Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance

May 15, 2025
pulisher
May 15, 2025

AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria

May 15, 2025
pulisher
May 14, 2025

AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace

May 14, 2025
pulisher
May 14, 2025

AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

AbCellera to begin Phase 1 trial for menopause treatment - Investing.com

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus

May 14, 2025
pulisher
May 14, 2025

AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus

May 14, 2025

Finanzdaten der Abcellera Biologics Inc-Aktie (ABCL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.44
price down icon 1.45%
$36.19
price up icon 0.86%
$22.62
price up icon 6.70%
$98.24
price up icon 0.64%
$108.26
price up icon 0.70%
biotechnology ONC
$244.32
price down icon 0.34%
Kapitalisierung:     |  Volumen (24h):